ERBB2 and breast cancer: The final results showed that ML39 SCFV and Tretazicar’s systemic IVT mRNA-loaded EVs at lower EV doses than previously caused almost complete growth arrest of human HER2+ breast cancer xenografts in non-thyroid mice [91].